Explore the latest in viral hepatitis, including recent advances in diagnosis and antiviral treatment of hepatitis B and C.
This JAMA Patient Page describes recent advancements in hepatitis C treatment.
A 68-year-old man has an undetectable hepatitis C (HCV) viral load, normal liver function tests, and an elevated vibration-controlled transient elastography (VCTE) measure after 12 weeks of antiviral treatment for HCV with stage 2 fibrosis by biopsy. How do you interpret the results?
This Viewpoint discusses a “Netflix” subscription model of drug payment being investigated by Louisiana for hepatitis C (HCV) drugs, in which a statewide coalition of payers would pay subscription fees over a fixed number of years for HCV drugs to treat all state residents and for efforts by the manufacturers to enhance treatment rates through patient outreach.
This cohort study examines the association of preoperative antiviral treatment with the incidences of microvascular invasion and posthepatectomy early tumor recurrence in adult patients with hepatitis B virus–related hepatocellular carcinoma.
This cohort study uses data from the Korean National Health Insurance Service database to compare the risk of hepatocellular cancer associated with entecavir vs tenofovir disoproxil fumarate in patients receiving long-term treatment for chronic hepatitis B infection.
This case report describes a patient with lichen myxedematosus that resolved after sofosbuvir-velpatasvir treatment for hepatitis C infection.
This cross-sectional study examines the association between alcoholism and cortical volume deficits in alcohol-dependent individuals.
This analysis of population-level data examines evidence of the association between body mass index and development of hepatocellular carcinoma among men and women with chronic hepatitis B virus infection.
This narrative review summarizes recent advances in the epidemiology, identification, natural history, diagnosis, treatment, and prognosis of chronic hepatitis B virus (HBV).
This Medical Letter review compares a newly approved 2-dose hepatitis B virus vaccine that uses a synthetic oligonucleotide immunostimulatory adjuvant, and is licensed for use in adults, with other commercially available 3-dose vaccines.
This JAMA Patient Page explains the prevention, transmission, symptoms, and treatment of hepatitis A.
A 30-year-old woman had widespread, erythematous, purpuric macules and papules on the abdomen and extremities. A skin punch biopsy showed extravasated erythrocytes, a neutrophilic infiltrate, fibrinoid necrosis, and broken-down neutrophils releasing nuclear debris. What would you do next?
This study describes the experience and virologic outcomes in a cohort of hepatitis C virus–infected homeless and marginally housed adults who were provided access to community-based treatment programs.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: